ArticleScientific reports2024

Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.

Dongmei Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.